liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Impact of systemic SARS-CoV-2 vaccination on mucosal IgA responses to subsequent breakthrough infection
Karolinska Inst, Sweden; Publ Hlth Agcy Sweden, Sweden.
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Show others and affiliations
2025 (English)In: EBioMedicine, E-ISSN 2352-3964, Vol. 120, article id 105912Article in journal (Refereed) Published
Abstract [en]

Background Mucosal IgA responses are central to protection against SARS-CoV-2 infection and viral transmission. While systemic immunity following SARS-CoV-2 infection and vaccination is thoroughly investigated, we have limited understanding of factors affecting the generation and boosting of mucosal IgA. Methods In this cohort study, we investigated factors influencing mucosal SARS-CoV-2 IgA responses among 879 healthcare workers enrolled in the longitudinal COMMUNITY study. Blood samples and clinical data were collected from all participants every four months since April 2020. SARS-CoV-2 immune histories are well characterized through national vaccine and infection registries along with regular monitoring of seroconversion of spike and/or nucleocapsid antigen. Regression models were developed to assess the influence of vaccinations and prior infections on the magnitude of SARS-CoV-2 spike-specific IgA in nasal secretions collected from the cohort in October 2022. Findings Mucosal SARS-CoV-2 spike-specific IgA was detected in 81% of participants, with a positive association with number of prior infections, indicating a booster effect by reinfection. The increased odds ratio of detectable mucosal IgA remained for at least 22 months post infection. There was a strong association between repeated systemic vaccinations and a lower magnitude of mucosal IgA responses. Moreover, the temporal sequence of infection and vaccination influenced mucosal IgA responses, with higher levels among participants with infection prior to systemic vaccination as compared to those with breakthrough infection as the first viral encounter. Interpretation The observation that repeated mucosal exposures elicit enhanced and long-lasting mucosal IgA responses strengthens the rationale for developing effective mucosal vaccines. While systemic vaccination remains essential for preventing severe disease, our findings suggest that it may influence subsequent generation of mucosal IgA trough a reduction of viral load and inflammation in the mucosa. This is highly relevant for both understanding the development of population immunity and for optimizing the timing of a sequential systemic and mucosal vaccination approach. Funding This study was supported by grants from Region Stockholm, and SciLifeLab and the Knut and Alice Wallenberg Foundation, SSMF and European Research Council. We thank the Public Health Agency of Sweden for support. Copyright (c) 2025 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Place, publisher, year, edition, pages
ELSEVIER , 2025. Vol. 120, article id 105912
Keywords [en]
SARS-CoV-2; Mucosal immunity; Antibody; IgA; Mucosal vaccination
National Category
Radiology and Medical Imaging
Identifiers
URN: urn:nbn:se:liu:diva-218156DOI: 10.1016/j.ebiom.2025.105912ISI: 001574039200001PubMedID: 40961508Scopus ID: 2-s2.0-105015848868OAI: oai:DiVA.org:liu-218156DiVA, id: diva2:2002533
Note

Funding Agencies|Region Stockholm; SciLifeLab; Knut and Alice Wallenberg Foundation; SSMF; European Research Council; Public Health Agency of Sweden

Available from: 2025-10-01 Created: 2025-10-01 Last updated: 2025-10-28

Open Access in DiVA

fulltext(1618 kB)108 downloads
File information
File name FULLTEXT01.pdfFile size 1618 kBChecksum SHA-512
e1885c05bc54b379c1a05786805720cd34805d257dd58a064817be7a9065e9bde0b7f4c01399c73f0c12101bd0d21da2b2f828ea693f417a1771b8d24af3cc40
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Klingström, Jonas
By organisation
Division of Molecular Medicine and VirologyFaculty of Medicine and Health Sciences
In the same journal
EBioMedicine
Radiology and Medical Imaging

Search outside of DiVA

GoogleGoogle Scholar
Total: 108 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 270 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf